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Viral respiratory infections are of major importance because of their capacity to cause of
a high degree of morbidity and mortality in high-risk populations, and to rapidly spread
between countries. Perhaps the best example of this global threat is the infectious
disease caused by the new SARS-CoV-2 virus, which has infected more than 4 million
people worldwide, causing the death of 287,000 persons according to the WHO’s
situation report on May 13, 2020. The availability of therapeutic tools that would be
used massively to prevent or mitigate the detrimental effects of emerging respiratory
viruses on human health is therefore mandatory. In this regard, research from the last
decade has reported the impact of the intestinal microbiota on the respiratory immunity.
It was conclusively demonstrated how the variations in the intestinal microbiota affect the
responses of respiratory epithelial cells and antigen presenting cells against respiratory
virus attack. Moreover, the selection of specific microbial strains (immunobiotics) with
the ability to modulate immunity in distal mucosal sites made possible the generation
of nutritional interventions to strengthen respiratory antiviral defenses. In this article,
the most important characteristics of the limited information available regarding the
immune response against SARS-CoV-2 virus are revised briefly. In addition, this review
summarizes the knowledge on the cellular and molecular mechanisms involved in the
improvement of respiratory antiviral defenses by beneficial immunobiotic microorganisms
such as Lactobacillus rhamnosus CRL1505. The ability of beneficial microorganisms
to enhance type I interferons and antiviral factors in the respiratory tract, stimulate
Th1 response and antibodies production, and regulate inflammation and coagulation
activation during the course of viral infections reducing tissue damage and preserving
lung functionally, clearly indicate the potential of immunobiotics to favorably influence the
immune response against SARS-CoV-2 virus.
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INTRODUCTION
A severe respiratory disease emerged in China in December
2019 and spread globally infecting more than 4 million people
worldwide and causing the death of 287,000 persons according to
theWHO’s situation report on May 13, 2020. This new infectious
disease was designated coronavirus disease 2019 (COVID-19)
and a virus from the coronavirus family was found to be the
causal agent of this pathology (WHO, coronavirus pandemic).
The virus was initially named 2019 new coronavirus (2019-
nCoV) but later renamed by the International Committee on
Taxonomy of Viruses as Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) (Coronaviridae Study Group of
the International Committee on Taxonomy of Viruses, 2020).
Since the WHO’s first situation report of SARS-CoV-2 infection
on January 21, 2020, public health systems and scientists have
rapidly learned about the transmission and mortality rates, the
clinical manifestations as well as the immune responses although
a more complete and precise understanding of the aspects of the
COVID-19 pathology could take several more months.
SARS-CoV-2 is an enveloped virus with a positive-sense,
single-stranded RNA genome of ∼30 kb, which shares some
sequence homology with Severe Acute Respiratory Syndrome
Coronavirus (SARS-CoV) (79% homology) and Middle
East Respiratory Syndrome Coronavirus (MERS-CoV) (50%
homology). The spike protein (also known as S protein) of
coronaviruses are involved in the viral entry into target cells.
The binding of the S protein to a specific cellular receptor allow
the viral attachment to the surface of target cells while the S
protein priming by cellular proteases facilitates the fusion of
viral and cellular membranes (Figure 1). Bioinformatic analysis
of the viral genome as well as in vitro and in vivo experiments
demonstrated that the human angiotensin-converting enzyme
2 (ACE2) acts as the cell receptor for SARS-CoV-2 (Bao et al.,
2020; Hoffmann et al., 2020a; Kim et al., 2020; Wang Q. et al.,
2020), while the serine protease TMPRSS2 is involved in the S
protein priming (Hoffmann et al., 2020b). In normal human
lungs, ACE2 is expressed mainly in alveolar epithelial type II
cells (or type II pneumocytes), which are the cells responsible
of producing the surfactant that reduces surface tension and
prevents the collapse of alveoli (Dobbs, 1989). Therefore, the
destruction of type II pneumocytes by SARS-CoV-2 infection
affects this critical function of respiratory cells impairing the gas
exchange function of the lung (Zhu et al., 2020). There is also
evidence of replication of SARS-CoV-2 in the upper respiratory
tract since the inoculation of this virus to surface layers of human
airway epithelial cells in vitro causes cytopathic effects and
cessation of the cilium beating of the cells (Zhu et al., 2020). On
the other hand, it was reported that SARS-Co-V directly infects
macrophages and T cells, a key feature in SARS-CoV-mediated
pathogenesis (Perlman and Dandekar, 2005; Shieh et al., 2005).
While a recent report suggested that SARS-CoV-2 can directly
infect T cells through S protein-mediated membrane fusion
(Wang X. et al., 2020), whether the virus is capable of infecting
other immune cells is still unknown. Studies reported that
the ACE2 is also expressed in several extrapulmonary tissues
including heart, kidneys, blood vessels, and intestine (Crackower
et al., 2002; Ding et al., 2004; Danilczyk and Penninger,
2006). This fact could explain at least partially the multiorgan
dysfunction observed in patients with severe COVID-19 (Guan
et al., 2020; Huang et al., 2020). Of note, another receptor,
CD147, has been implicated in mediating host cell invasion by
SARS-CoV-2 (Wang K. et al., 2020). However, the role of CD147
and SARS-CoV-2 interaction in the pathology of COVID-19
needs further research.
SARS-CoV-2 binds to its receptor and enters the cells through
endocytosis (Figure 1). Then, viral RNA is released into the
cytosol and the virus exploits the cell machinery to replicate.
Finally, SARS-CoV-2 is excreted from the cell by exocytosis. The
rapid viral replication cause massive epithelial cell apoptosis,
vascular leakage, and induce the release of pro-inflammatory
cytokines and the recruitment of inflammatory cells (Jamilloux
et al., 2020). The control of the viral replication and the
efficient regulation of the inflammatory response determine the
outcome of this infectious disease (Figure 1; Jamilloux et al.,
2020; Merad and Martin, 2020; Tay et al., 2020). The majority
of the persons infected with SARS-CoV-2 (80%) exhibit mild to
moderate symptoms, while approximately 15% progress to severe
pneumonia and 5% develop acute respiratory distress syndrome
(ARDS), septic shock, and/or multiple organ failure (Chan et al.,
2020; Ding et al., 2020; Huang et al., 2020; Prompetchara et al.,
2020; Wu et al., 2020).
A high-quality clinical study performed by a group of
clinicians and scientists from the University of Hong Kong
in the city of Shenzhen provided several important clinical
features of COVID-19 (Chan et al., 2020), which were later
confirmed by several clinical trials around the world (Bai et al.,
2020; Ding et al., 2020; Huang et al., 2020; Prompetchara
et al., 2020; Wu et al., 2020). This pioneering study and the
subsequent clinical investigations found a series of characteristics
of COVID-19 that can be summarized as follows: (a) a
high transmissibility of SARS-CoV-2 within the family context
providing concrete evidence for human-to-human transmission,
(b) variable clinical manifestations ranging frommild respiratory
symptoms to severe ARDS and multiple organ failure, (c)
more severe clinical abnormalities seen in older patients and/or
patients with other co-morbidities (diabetes, hypertension,
cardiovascular diseases), (d) the presence of SARS-CoV-2 RNA
in samples of asymptomatic persons highlighting the possibility
for transmission of the virus from asymptomatic carriers and,
(e) the presence of gastrointestinal symptoms in some persons
suggesting the possibility for gastrointestinal involvement in
SARS-CoV-2 infection and fecal-oral transmission.
The most common symptoms of COVID-19 include
respiratory symptoms such as cough, sore throat, shortness of
breath, and pneumonia, as well as fever, fatigue, and in very few
cases diarrhea and vomiting (Chan et al., 2020; Prompetchara
et al., 2020). Secondary infections have been also reported to
be involved in severe and fatal cases of SARS-CoV-2 infection
(Huang et al., 2020). Around 10% of the fatal cases of COVID-19
have identified co-infections of SARS-CoV-2 with Influenza
Virus (IFV) (Ding et al., 2020; Huang et al., 2020; Wu et al.,
2020) and respiratory bacterial pathogens (Wang J. et al.,
2020). Importantly, the role of the immune responses in the
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FIGURE 1 | Infection and modulation of the immune system by SARS-CoV-2. In most individuals, SARS-CoV-2 infection triggers and efficient and timely production of
type I IFNs and inflammatory cytokines by epithelial cells and immune cells creating an antiviral state and inducing the recruitment of additional immune cells that
collaborate to clear the infection in the lung, with minimal inflammation and damage. This type of immune response is associated to mild or moderate forms of
COVID-19 and patients finally recover. In high-risk populations such as the elderly and persons with comorbidities, a dysfunctional immune response is triggered by
SARS-CoV-2 infection. A severe type of COVID-19 characterized by a cytokine storm that mediates widespread lung inflammation, coagulopathies, organ failure, and
death occurs in some patients.
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SARS-CoV-2 infection-induced lung and systemic damage has
been highlighted by recent studies (Cao, 2020; Jamilloux et al.,
2020; Tay et al., 2020). The information regarding the immune
responses to SARS-CoV-2 was the result of limited investigations
and mainly from extrapolations using insights learned from
the outbreaks of SARS-CoV and MERS-CoV. Both innate and
adaptive immune responses are stimulated by SARS-CoV-2,
however; uncontrolled inflammatory responses and impaired
adaptive immunity are characteristics of COVID-19 (Cao, 2020;
Merad and Martin, 2020; Tay et al., 2020). The infiltration
of inflammatory cells in the lung, lymphopenia, exhausted
lymphocytes, and a cytokine storm actively participate in tissue
damage, both locally and systemically.
The availability of therapeutic tools that could be used
massively to prevent or mitigate the detrimental effects of
emerging respiratory viruses such as SARS-CoV-2 on human
health is therefore mandatory. In this regard, research from
the last decade has reported the impact of the intestinal
microbiota on the respiratory immunity. It has been conclusively
demonstrated how variations in the intestinal microbiota can
affect the responses of respiratory epithelial cells and antigen
presenting cells against respiratory virus attack, influencing
innate immune responses, and the subsequent adaptive
immunity. Moreover, the selection of specific microbial strains
with the ability to modulate immunity in distal mucosal sites
made possible the generation of nutritional interventions to
strengthen respiratory antiviral defenses (Villena et al., 2019). In
this article, the most important characteristics of the available
information regarding the immune response against SARS-CoV-
2 virus are revised briefly. In addition, this review summarizes the
knowledge on the cellular and molecular mechanisms involved
in the improvement of respiratory antiviral defenses by beneficial
microorganisms such as Lactobacillus rhamnosus CRL1505.
The ability of orally administered beneficial microorganisms
to differentially modulate the innate and adaptive immune
responses in the respiratory tract and systemically clearly
indicate the potential of immunobiotics to favorably influence
the immune response against SARS-CoV-2 virus.
RELEVANT FEATURES OF THE IMMUNE
RESPONSES TO SARS-CoV-2
In this section, we summarize the principal findings of SARS-
CoV-2 infection and the extrapolations to SARS-CoV and
MERS-CoV that were made by scientists in an attempt to
establish a definitive view of both the protective immune
response and the immunopathology in COVID-19. We highlight
the immunological mechanisms involved in the response to
SARS-CoV-2 infection that could be potentially modulated by
nutritional immunobiotic interventions.
Respiratory Innate Antiviral Immune
Response and SARS-CoV-2
The first barrier involved in the protection of the respiratory
mucosa form viral attacks is the respiratory epithelium through
its capacity to produce a mucus layer that is in constant
displacement because of the action the ciliary movement. The
viral particles that reach the mucus layer in the conducting
airways can be trapped and swept into the throat and eventually
removed through the gastrointestinal tract. When respiratory
viruses successfully overcome this first barrier, they interact with
respiratory epithelial cells from the conducting airways and/or
the deep lung, starting their attachment and internalization
to initiate their replication (Hammad and Lambrecht, 2011).
Those respiratory epithelial cells as well as antigen presenting
cells including dendritic cells (DCs) from the airways and
the lung parenchyma, and alveolar macrophages are the first
to encounter viruses that enter the respiratory tract. During
the viral replication, several pathogen-associated molecular
patterns (PAMPs) are exposed, which are recognized by pattern-
recognition receptors (PRRs) expressed in respiratory epithelial
cells, DCs and alveolar macrophages (Neyt and Lambrecht, 2013;
Garbi and Lambrecht, 2017). The PAMPs-PPRs interaction leads
to the activation of several signaling pathways that induce the
production of type I and II interferon (IFNs) and inflammatory
cytokines. IFNs such as IFN-β produced by virus-infected cells
are able to act on neighboring immune and non-immune
cells promoting an antiviral state through the up-regulation of
hundreds of interferon-stimulated genes (ISGs) that counteract
viral replication. On the other hand, inflammatory cytokines such
as TNF-α, IL-1β, IL-6, IL-8, MCP-1, and IL-17 among others
induce the recruitment and activation of immune cells (NK cells,
neutrophils, and macrophages) to promote the elimination of
virus-infected cells (Hammad and Lambrecht, 2011; Neyt and
Lambrecht, 2013; Garbi and Lambrecht, 2017). These defense
mechanisms of the innate antiviral immunity are important
because they are in several cases sufficient to induce the
complete elimination of the respiratory virus or instead, to
support the generation of efficient cellular and humoral adaptive
immune responses.
The proper and timely production of type I IFNs in the
respiratory tract in response to virus infection is crucial to
suppress viral replication and dissemination at an early stage. It
was shown that coronaviruses are particularly adapted to evade
immune detection and dampen this initial antiviral response
mediated by type I IFNs (Lessler et al., 2009; Kindler et al., 2016;
Channappanavar and Perlman, 2017). An active suppression of
IFNs-mediated antiviral response was described for both SARS-
CoV and MERS-CoV. These two coronaviruses use multiple
strategies to obstruct the type I IFN production and the signaling
downstream of the IFNAR. SARS-CoV and MERS-CoV are able
to modify the ubiquitination and the degradation of the adaptor
molecules mitochondrial antiviral-signaling proteins (MAVs),
TNF receptor-associated factor 3 (TRAF3) and TRAF6 impairing
type I IFN induction (Kindler et al., 2016). In addition, both
coronaviruses are capable of inhibiting interferon regulatory
factor 3 (IRF3) nuclear translocation (Kindler et al., 2016).
The strength of the interference with the signaling leading to
type I IFN production was associated with the disease severity
(Channappanavar and Perlman, 2017). This mouse model of
SARS-CoV infection demonstrated that the deregulated type
I IFN production was the main cause of lethal pneumonia
and that inflammatory phagocytes actively participated in the
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inflammatory damage. The delayed type I IFN production in
response to SARS-CoV or MERS-CoV infection compromises
the early viral control, leading to influx of hyperinflammatory
neutrophils and monocytes-macrophages, which contribute to
lung immunopathology through the production of inflammatory
factors (Channappanavar and Perlman, 2017). The same work
demonstrated that exogenous type I IFNs have both beneficial
and detrimental effects depending on the time of administration.
Early administration of IFNs contributed to protection against
coronavirus infection while delayed IFNs treatment potentiated
inflammatory-damage. Interestingly, the efficient impairment of
the earlier type I IFNs response by coronaviruses was proposed
to explain why SARS-CoV and MERS-CoV tend to have a longer
incubation period (up to 11 days) when compared to other
respiratory viruses (up to 4 days for IFV) (Lessler et al., 2009).
It has been demonstrated that for SARS-CoV-2 the response
to viral infection by type I IFN is suppressed (Rokni et al.,
2020) and therefore, similar to other respiratory coronaviruses
the degree of immune interference would be involved in both
the lung immunopathology and the extended incubation period.
Moreover, the delayed early activation of the antiviral innate
immune response has been proposed to explain the SARS-
CoV-2 transmission from asymptomatic infected individuals
(Prompetchara et al., 2020). Importantly, recent in vitro studies
showed that SARS-CoV-2 is sensitive to the treatment with IFN-
α or IFN-β demonstrating the potential efficacy of human type
I IFNs therapy for suppressing SARS-CoV-2 infection (Mantlo
et al., 2020).
Respiratory Adaptive Antiviral Immune
Response and SARS-CoV-2
Research of the adaptive immune responses against respiratory
coronaviruses strongly indicated that appropriate Th1 and
humoral immune responses are needed for the successful control
of SARS-CoV and MERS-CoV infections (Prompetchara et al.,
2020) and probably also for SARS-CoV-2. Studies of T cell
responses in patients infected with SARS-CoV showed that
virus-specific CD8+ T cells were more frequent than CD4+
T cells (Li et al., 2008). Moreover, those virus-specific T cells
had a polyfunctional phenotype with CD4+ T cells producing
IFN-γ, TNF-α, and IL-2 and CD8+ T cells producing IFN-
γ and TNF-α and having a degranulated state. Of note,
patients resolving the infection had a strong Th1 response that
correlated with higher neutralizing antibodies production. In
contrast, fatal cases of SARS-CoV infection showed prevalence
of Th2 cytokines (IL-4, IL-5, IL-10) in serum together with
low production of neutralizing antibodies (Li et al., 2008).
Interestingly, experiments with MERS-CoV demonstrated the
ability of the virus to down-regulate the expression ofMHC-I and
MHC-II molecules in macrophages and DCs, impairing antigen
presentation, and diminishing T cells activation (Shokri et al.,
2019). Epigenetic analysis suggested that DNAmethylation plays
a crucial role in MERS-CoV-mediated antagonism of antigen-
presentation gene expression (Menachery et al., 2018). Although
these molecular mechanisms have not been investigated in detail
for SARS-CoV-2, clinical studies conducted since the beginning
of the COVID-19 pandemic have made clear the ability of this
virus to affect the adaptive immunity (Baruah and Bose, 2020;
Li G. et al., 2020; Rokni et al., 2020). A transcriptomic study
evaluating the expression of immune genes in patients suffering
from COVID-19 found significantly reduced levels of HLA-
DRB1, HLA-DMA, HLA-DMB, IL23A, and CD74 in severe cases
indicating an impairment of the adaptive immune response (Ong
et al., 2020).
A common finding in the laboratory analysis of patients
infected with SARS-CoV-2 is the simultaneous neutropenia and
lymphopenia (Chen X. et al., 2020; Huang et al., 2020; Qin et al.,
2020; Shi et al., 2020; Xu et al., 2020; Zhang B. et al., 2020a; Zheng
et al., 2020). In fact, the increase in the neutrophil-to-lymphocyte
ratio usually indicates higher disease severity and poor clinical
outcome. Reduced numbers of total T cells, B cells, and NK
cells are consistently observed in patients suffering COVID-19
(Huang et al., 2020; Qin et al., 2020; Shi et al., 2020; Xu et al.,
2020). Decreased numbers of CD4+ and CD8+ T cells as well
as increased expression of exhaustion markers such as NKG2A
in NK cells and CD8+ T cells have been detected in patients
infected with SARS-CoV-2 (Chen X. et al., 2020; Zheng et al.,
2020). In addition, the strong decline of CD3+CD4+IFN-γ+ T
cells and the tendency in the reduction of regulatory T cells was
more pronounced in severe cases (Liu et al., 2020; Pedersen and
Ho, 2020; Qin et al., 2020).
On the other hand, the humoral immune response, especially
the production of neutralizing antibodies, had a protective
role against respiratory coronavirus infections. Neutralizing
antibodies are capable of limiting the infection at a later phase
and prevent reinfection in the future (Gorse et al., 2020). Studies
in patients recovered from SARS-CoV infection demonstrated
that almost 90% of them had virus-specific IgG neutralizing
antibodies after 2 years of the infection (Hsueh et al., 2004; Liu
et al., 2006). In contrast, it was shown an antibody-dependent
enhancement of virus infection for the MERS-CoV (Wan et al.,
2020). In fact, a neutralizing monoclonal antibody targeting
the receptor-binding domain of the MERS-CoV S protein can
enhance viral entry (Wan et al., 2020). Large-scale single-cell
RNA sequencing of B cells isolated from convalescent patients
of SARS-CoV-2 infections demonstrated the presence of SARS-
CoV-2 spike glycoprotein specific neutralizing antibodies (Shen
et al., 2020). It was reported that patients with severe disease
frequently had an increased IgG response and a higher titer
of total antibodies, which was associated with worse outcome
(Zhang B. et al., 2020b; Zhao et al., 2020). On the contrary,
the convalescent plasma containing neutralizing antibodies was
used successfully to improve the outcome of critically ill
patients infected with SARS-CoV-2 who developed ARDS (Shen
et al., 2020). Interestingly, a clinical study that investigated the
characteristics of the humoral immune response in SARS-CoV-
2-infected and uninfected children found that there was rapid
production of protective antibodies after first virus exposure
(Zhang Y. et al., 2020b).Moreover, the work reported thatmost of
the SARS-CoV-2 specific IgM switched to IgG within 1 week and
suggested that this efficient humoral immune response should
be responsible of the milder symptoms of SARS-CoV-2-infected
children when compared to adults. These findings indicate that
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the type and concentration of antibodies produced in response
to respiratory coronaviruses are able to affect positively or
negatively the resolution of the infection.
Respiratory Inflammatory Response and
SARS-CoV-2
Highly pathogenic coronaviruses such as SARS-CoV or
MERS-CoV predominantly infect the lower respiratory tract
where they rapidly replicate inducing massive inflammatory
cell infiltration and elevated pro-inflammatory cytokine and
chemokine responses resulting in lung injury (Channappanavar
and Perlman, 2017; Merad and Martin, 2020; Tay et al., 2020).
In SARS-CoV-infected patients with severe disease, there are
high serum levels of pro-inflammatory cytokines such as IL-1β,
IL-6, IL-12, and IFN-γ as well as chemokines including IL-8,
CCL2, CXCL9, and CXCL10 when compared to patients with
uncomplicated SARS (Channappanavar and Perlman, 2017).
This so-called “cytokine storm” actively participates in the
inflammatory-mediated lung injury and viral sepsis as well as in
other complications including pneumonitis, ARDS, respiratory
failure, shock, and organ failure. In line with these previous
findings for SARS-CoV or MERS-CoV (Nicholls et al., 2003;
Wong et al., 2004; Mahallawi et al., 2018), the presence of both
lymphopenia and cytokine storm seems to play a critical role in
the pathogenesis of SARS-CoV-2 (Merad and Martin, 2020; Tay
et al., 2020). A study of severe cases of COVID-19 hospitalized
patients demonstrated high levels of pro-inflammatory cytokines
in serum samples including IL-2, IL-7, IL-10, G-CSF, CCL2,
CCL3, CCL4, CXCL10, and TNF-α (Huang et al., 2020). Those
finding were corroborated by several subsequent studies (Chen
C. et al., 2020; Qin et al., 2020). The transcriptional profile
of whole blood samples from severe cases of SARS-CoV-2
infection revealed that the most up-regulated genes clustered
in the “Toll-like receptor (TLR) and inflammatory response”
and the “Cytokine signaling” pathways (Ong et al., 2020).
The study also concluded that expression of IL1A and IL1B
preceded the nadir of respiratory function (Ong et al., 2020). In
addition, it was reported that the peripheral blood of patients
with severe COVID-19 contained a significant proportion of
CD14+CD16+ monocytes producing IL-6, highlighting the
role of this immune cell population in the hyper-inflammation
induced by SARS-CoV-2 infection (Wen et al., 2020; Zhang Y.
et al., 2020a).
Recent studies evaluating the broncho-alveolar fluid of
patients with severe SARS-CoV-2 infection demonstrated
elevated levels of the chemokines CCL2 and CCL7, which
are known to be potent chemotractant for the recruitment
of CCR2+ monocytes (Zhou et al., 2020). Moreover, single-
cell RNA sequencing analysis of cells from broncho-alveolar
lavages collected from patients with mild or severe COVID-19
indicated that the former group had significantly higher levels of
inflammatory monocytes while the resident alveolar macrophage
population was diminished (Liao et al., 2020). Therefore, the
un-regulated production of pro-inflammatory cytokines during
SARS-CoV-2 infection may lead to a massive infiltration of
neutrophils and macrophages into the lungs promoting alveolar
damage and diffuse thickening of the alveolar wall. The cytokine
storm promoted by SARS-CoV-2 may also participate in the
tissue damage in the heart, liver and kidney, as well as in spleen
atrophy and lymph node necrosis observed in deceased patients
(Cao, 2020).
Coagulation Activation and SARS-CoV-2
In addition to changes in white blood cell populations and
cytokine levels, laboratory analyzes of patients infected with
SARS-CoV-2 often show thrombocytopenia (Yin et al., 2020;
Zhang B. et al., 2020a), alterations of prothrombin time and
increases in the levels of D-dimers and fibrinogen degradation
products (FDPs) (Huang et al., 2020; Yin et al., 2020; Zhang D.
et al., 2020b). Elevation in D-dimers is reflective of increased
thrombosis risk that may lead to acute coronary syndrome in
COVID-19 patients (Guan et al., 2020; Huang et al., 2020;
Wang D. et al., 2020). A study in which critical SARS-CoV-2-
infeceted patients were evaluated during their attention in the
intensive care unit reported elevated D-dimers and increases in
FDPs (Zhang D. et al., 2020b). Another clinical study compared
hemostatic parameters between groups of SARS-CoV-2-inefected
patients that survived or not to the infection. In non-survivors,
higher D-dimers and FDPs levels, longer prothrombin time
and activated partial thromboplastin time were observed when
compared to the survivors group (Tang et al., 2020). In both
studies, disseminated intravascular coagulation was observed
in fatal cases. Han et al. (2020) also reported differences in
the levels of D-dimers, fibrinogen, and FDPs when patients
with milder forms of SARS-CoV-2 infection were compared
with the severe cases. Interestingly, the work also demonstrated
diminished values of antithrombin in COVID-19 patients than in
healthy controls.
It should be noted that the hemostatic alterations were more
notable in patients requiring intensive care unit assistance (Guan
et al., 2020; Huang et al., 2020; Wang D. et al., 2020). In
fact, abnormal coagulation results were associated with poor
prognosis of COVID-19 and the existence of disseminated
intravascular coagulation was common in deaths associated with
this infectious disease. In the points of lung injury mediated by
viral replication and cytokine release, there is an activation of
monocytes and endothelial cells that increase their secretion of
tissue factor (TF) and von Willebrand factor. These hemostatic
changes results in the circulation of free thrombin, activation
of platelets and stimulation of fibrinolysis creating a pro-
thrombotic state and secondary hyperfibrinolysis condition.
The disseminated intravascular coagulation mediates pulmonary
congestion with microvascular thrombosis as well as other
thrombosis and vascular occlusive events that are observed in
critically ill COVID-19 patients (Wang J. et al., 2020).
Intestinal Infection and SARS-CoV-2
It was demonstrated that there is a ubiquitous expression of
ACE2, the viral receptor for SARS-CoV-2, in the luminal surface
of the gastrointestinal tract, particularly in enterocytes. This fact
has made scientists to wonder if the gastrointestinal mucosa
could serve as a secondary site for SARS-CoV-2 infection
(Gheblawi et al., 2020; Wong et al., 2020). In support of
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this hypothesis, it was shown that 5 to 10% of the patients
infected with SARS-CoV-2 developed intestinal symptoms such
as diarrhea, vomiting, and abdominal pain (Guo et al., 2020;
Ji et al., 2020; Li L. et al., 2020; Song et al., 2020; Wang D.
et al., 2020; Yeo et al., 2020). Despite the fact that the percentage
of SARS-CoV-2-infecetd patients with intestinal symptoms is
less than that found for SARS-CoV or MERS-CoV (20–25%)
(Wong et al., 2020), those studies suggest that SARS-CoV-2 can
actively infect and replicate in the gastrointestinal tract. The
possibility that the virus may replicate efficiently in the intestinal
tract, opens other questions related to both its pathogenesis
and its transmission. Studies in experimental animals in which
the ACE2 was disrupted, demonstrated that gut dysbiosis is
a prevalent finding (Cole-Jeffrey et al., 2015; Oliveira et al.,
2020). Moreover, the intestinal microbial dysbiosis associated to
ACE2 alterations was associated to exacerbations of diabetes,
hypertension, and pulmonary diseases (Cole-Jeffrey et al., 2015;
Oliveira et al., 2020). In line with these findings in animal models,
studies performed during SARS-CoV outbreak in the early
2000s demonstrated that patients with viral shedding from the
gastrointestinal tract had amore aggressive clinical course (Leung
et al., 2003; Cheng et al., 2004). Some evidence also support that
SARS-CoV-2 may induce alterations of intestine-blood barrier
promoting the abnormal absorption of microbial molecules
or the spread of bacteria that strongly stimulate the systemic
inflammatory response contributing to multiorgan dysfunction
and septic shock (Guan et al., 2020; Huang et al., 2020; Wang D.
et al., 2020). On the other hand, the replication of the virus in
the intestinal tract highlight the importance of fecal-oral route in
SARS-CoV-2 transmission, which could be of relevance in certain
circumstances such as crowded conditions of large family groups
(Yuen et al., 2020). This has important implications to the disease
management, transmission, and infection control.
MODULATION OF RESPIRATORY
IMMUNITY BY THE INTESTINAL
MICROBIOTA
The effect of the intestinal microbiota on the immune responses
in distal mucosal sites and its impact on the outcome of
respiratory infections has been explored recently. In this regard,
some studies reported an important role for intestinal microbiota
in maintaining respiratory antiviral immunity through the
modulation of the immune response both at the steady state
as well as in response to the viral attack (Ichinohe et al., 2011;
Abt et al., 2012; Bradley et al., 2019). Remarkably, most studies
demonstrated a significant impact of the intestinal microbiota
in the respiratory innate antiviral defense mechanisms thought
its influence on (a) respiratory epithelial cells, (b) respiratory
DCs, and (c) pulmonary macrophages. In addition, the influence
of the intestinal microbiota on the antiviral innate immunity
also modifies the respiratory antiviral cellular and humoral
adaptive immune responses (Figure 2). (a) The influence of
intestinal microbiota on the antiviral immune response mediated
by respiratory epithelial cells was demonstrated by bone marrow
chimera experiments, which identified non-immune respiratory
cells as crucially important for early antiviral immunity and
their interaction with immune cells important for late antiviral
resistance (Bradley et al., 2019). It was shown that the intestinal
microbiota influence the IFN-α/β receptor (IFNAR) surface
expression in respiratory epithelial cells, which in front of a
respiratory virus attack are able to respond more efficiently
to type I IFNs stimulation with enhanced ISGs levels. Thus,
the microbiota-driven IFN signature in the respiratory epithelia
impedes early virus replication (Bradley et al., 2019). (b) The
influence of the intestinal microbiota on the antiviral immune
response mediated by DCs was reported by Ichinohe et al.
(2011). It was demonstrated that the intestinal microbiota, in
particular Gram positive bacterial populations, are involved in
the appropriate distribution and activation of respiratory DCs at
steady state. Intact intestinal microbiota support the expression
of pro–IL-1β, pro–IL-18, and NLRP3 at steady state, and this
inflammasome activation improve the activation and migration
of DCs from the lung to the draining lymph node after the
challenge with IFV. This effect of the intestinal microbiota
was of importance for the efficient activation of virus specific
CD8+ and CD4+ T cells, the expansion of B cells and the
production of virus-specific antibodies (Ichinohe et al., 2011). (c)
The effect of the intestinal microbiota on the antiviral immune
response mediated by macrophages was studied by Abt et al.
(2012). It was also shown that the intestinal microbiota help
to maintain the optimal functions of pulmonary macrophages.
The intestinal microbiota is involved in the efficient capacity of
pulmonary macrophages to produce type I IFNs and antiviral
ISGs including Irf7, Mx1, and Oas1 to limit viral replication
(Abt et al., 2012). In addition, the intestinal microbiota
positively influence the ability of pulmonary macrophages to
support the generation of virus-specific antibodies as well as
virus-specific T cells. In intestinal microbiota-depleted mice,
macrophages have a reduced expression of MHC-I and CD86
molecules. An impaired number of IFV-specific CD8+ T cells
as well as a reduced ability of these cells to produce IFN-
γ, TNF-α, IL-2, and MIP-1α was also observed (Abt et al.,
2012).
Those studies demonstrated that the signals provided by the
intestinal microbiota act at multiple levels in the respiratory
mucosa stimulating an antiviral state in non-immune cells
and innate immune cells that would allow an efficient control
of viral replication early during the infection. The improved
respiratory innate antiviral immune response would enhance
the functionality of immune cells leading to improved humoral
and cellular adaptive immune responses later in the course of
viral infection (Figure 2). Although these effects of the intestinal
microbiota have been documented for IFV infection (Ichinohe
et al., 2011; Abt et al., 2012; Bradley et al., 2019), it should be
considered that the cellular and molecular mechanisms involved
in the innate antiviral immune response are not virus specific
and therefore, they are similar for all the respiratory viruses.
Then, it can be assumed that the beneficial microbes in the
intestinal tract may favorably influence the innate immune
responses to other respiratory viruses as well. In this regard,
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FIGURE 2 | Modulation of respiratory antiviral immunity by intestinal microbiota. Proposed mechanism for the distal immunomodulation induced by the intestinal
microbiota and the enhancement of the resistance against viral infections through the improvement of the respiratory innate and adaptive antiviral immune responses.
it was recently demonstrated that a high-fiber diet improved
the production of acetate by the intestinal microbiota of mice
and that this metabolic product modulated the activity of
respiratory IFN-β and increased the expression of ISGs in the
lung (Antunes et al., 2019). The immunological changes induced
in the respiratory tract by the dietary treatment significantly
increased the resistance of mice to the challenge with respiratory
syncytial virus (RSV).
The exact origin and nature of the signals used by the intestinal
microbiota to modulate the respiratory antiviral immunity
remain to be determined. Four probable mechanisms have been
proposed, which are not mutually exclusive, to explain the
effect of the intestinal microbiota on the respiratory immunity
(Figure 2). The existence of the so-called common mucosal
immune system implies that the immune cells activated in
one mucosal tissue can mobilize and reach distant mucosal
sites where they can influence immune responses. Then, the
mobilization of B and T cells from the intestinal mucosa to the
respiratory tract could be involved in the beneficial effects exerted
by the intestinal microbiota (Kitazawa and Villena, 2014; Zelaya
et al., 2016). It was also hypothesized that immune factors such as
cytokines and growth factors produced in the intestinal mucosa
in response to microbiota stimulation, can be released to blood
and act systemically or in other mucosal tissues (Kitazawa and
Villena, 2014; Zhang D. et al., 2020a). There is also evidence that
microbial products can be absorbed in the intestine and circulate
throughout the host (Macpherson and Uhr, 2004; Clarke et al.,
2010). It is speculated that some microbial-associated molecular
patterns (MAMPs) derived from the intestinal microbiota can
be adsorbed and transported to extraintestinal sites where they
stimulate PRRs expressed in non-immune and immune cells
influencing the immune responses. Perhaps the best example
of this mechanism was given by Clarke et al. (2010) who
demonstrated that the peptidoglycan translocated from the gut
microbiota to the systemic circulation was detected by NOD1,
resulting in enhanced systemic innate immunity mediated by
neutrophils. In addition, microbial metabolites that are adsorbed
in the intestine have been associated to differential modulation
of respiratory immune responses. This effect has been called
“metabolic reprograming” and implies that metabolites such as
circulating short-chain fatty acids (SCFAs) (Trompette et al.,
2014), desaminotyrosine (Steed et al., 2017), and docosahexanoic
acid (Fonseca et al., 2017) can reach innate immune cells in the
respiratory tract and improve their responses to viral infections.
Interestingly, the studies with germ-free as well as antibiotic-
treated mice recolonized with bacteria demonstrated that the
changes induced by the intestinal microbiota are reversible and
more importantly, tunable (Ichinohe et al., 2011; Abt et al.,
2012; Steed et al., 2017; Bradley et al., 2019). Moreover, it
was shown that not all commensal bacteria could contribute
equally to the immunocompetence in the lung (Ichinohe et al.,
2011). These findings have opened the possibility of exploring
particular strains of beneficial bacteria with immunomodulatory
capacities, referred to as immunobiotics, in order to increase
antiviral defenses in the respiratory tract. Then, several
immunomodulatory beneficial microbial strains, mainly form the
Lactobacillus and Bifidobacterium species, have been tested in
their capacities to modulate the respiratory antiviral immune
response when orally administered (reviewed in Zelaya et al.,
2016; Villena et al., 2019).
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MODULATION OF HUMAN RESPIRATORY
ANTIVIRAL IMMUNITY BY
IMMUNOBIOTICS
A growing number of studies have examined the effect of
immunobiotic nutritional interventions on the incidence, the
duration and severity of respiratory infections in humans.
Several clinical trials, systematic reviews and meta-analyses have
suggested that immunobiotics may be effective in improving
the resistance of children, adults, and even the elderly against
respiratory infections such as the common cold and influenza-
like symptoms. A meta-analysis of four clinical trials in which
1,800 children participated demonstrated that L. rhamnosus GG
administration reduced incidence of acute otitis media, the risk of
upper respiratory infections and the days of antibiotic treatments
(Liu et al., 2013). Similarly, a meta-analysis of 23 double-
blinded, randomized, and placebo-controlled trials involving
more than 6,000 children demonstrated that immunobiotic
treatments are capable of reducing the numbers of respiratory
tract infections cases, days of illness per person, and days
absent from school compared to placebo groups (Wang et al.,
2016). Interestingly, immunobiotic intervention was shown to
reduce the episodes of viral respiratory infections even in
asthmatic children (Ahanchian et al., 2016). The improvement
of respiratory defenses were also demonstrated in healthy adults.
The nutritional intervention with the well-know immunobiotic
strain L. casei Shirota was capable of diminishing the cumulative
number of respiratory infectious episodes and the cumulative
days with symptoms per person (Shida et al., 2017). An increase
in blood leukocyte, neutrophil, and NK cell counts and activity
was found in shift workers treated with L. casei DN-114001.
The work also registered a significant reduction in the incidence
of respiratory infections in DN-114001-treated adults when
compared to the placebo group (Guillemard et al., 2010a).
Moreover, the same probiotic treatment was found to diminish
the incidence and severity of upper respiratory tract infections in
the elderly (Guillemard et al., 2010b). Middle-aged and elderly
people treated with a probiotic yogurt containing L. paracasei
N1115 have a reduced incidence of acute upper respiratory tract
infections and higher blood CD3+ T cells levels were associated
to the beneficial effect (Pu et al., 2017). Two independent studies
conducted in healthy elderly individuals demonstrated that the
administration of L. delbrueckii ROLL1073R-1 augmented NK
cells activity and reduced the risk of catching the common cold
(Makino et al., 2010).
Although the clinical studies demonstrated the beneficial
effect of immunobiotics on human respiratory infections, few
of them investigated specific viral etiology from the respiratory
tract, and reported a significant decrease in viral load (Lehtoranta
et al., 2014). On the other hand, the impact of immunobiotics on
the human respiratory and systemic antiviral immune responses
have been clearly demonstrated in several studies in which the
immunobiotic interventions acted as efficient adjuvants on IFV
vaccination (reviewed in Zelaya et al., 2016).
Collectively, research has shown that some immunobiotic
strains are capable of making a difference in the host’s response to
respiratory viral infections. However, there are variable findings
in the effect of immunobiotics on respiratory tract infections in
humans. This fact could be related to several factors including the
specific strain, the duration of regimens, administration forms,
doses, and follow-up time. Therefore, the role of immunobiotics
on specific viruses needs deeper research with randomized,
double-blind, and placebo-controlled trials in different age
populations. Moreover, the cellular and molecular mechanisms
involved in the beneficial effects of each particular strain have not
been extensively evaluated. Those kind of studies are necessary to
provide solid scientific basis to promote the use of immunobiotics
in the prevention of respiratory viral infections.
In a randomized controlled trial in children, it was
demonstrated that the immunobiotic strain L. rhamnosus
CRL1505, administered in a yogurt, improvedmucosal immunity
and reduced the incidence and severity of viral intestinal and
respiratory infections (Villena et al., 2012b). Since then and for
more than a decade, we have dedicated our efforts to perform
detailed mechanistic studies by using in vivo, in vitro, and
in silico models to characterize the antiviral properties of L.
rhamnosus CRL1505 (Figure 3). The most relevant findings of L.
rhamnosus CRL1505’s impact on mucosal antiviral immunity are
summarized below.
MODULATION OF MUCOSAL ANTIVIRAL
IMMUNITY BY L. rhamnosus CRL1505
Respiratory Innate Antiviral Immune
Response and L. rhamnosus CRL1505
In order to study in depth the mechanisms involved in the
enhancement of respiratory antiviral immunity mediated by L.
rhamnosus CRL1505, we conducted studies in animal models
using two respiratory viruses of great importance in public
health: RSV and IFV (Chiba et al., 2013; Zelaya et al., 2014).
Our results showed that orally administered CRL1505 strain was
capable of significantly reducing viral titers in lungs, lessened
pulmonary damage, and increased survival of mice in response
to RSV (Chiba et al., 2013) or IFV challenges (Zelaya et al.,
2014). The protective effect induced by L. rhamnosus CRL1505
was associated its ability to differentially modulate the innate
antiviral immune response, particularly to its capacity to improve
the levels of type I IFNs in the respiratory tract. Mice treated
with the immunobiotic strain had significantly higher levels
of IFN-β in the respiratory mucosa after the nasal challenge
with TLR3 agonist, RSV, or IFV (Villena et al., 2012a; Chiba
et al., 2013; Zelaya et al., 2014). Type I IFNs binding to their
cognate cell surface receptors activate positive feedback loops
that amplifies the expression of IFNs as well as hundreds
of different ISGs. This IFNs release then efficiently amplifies
the expression of antiviral proteins targeting a variety of viral
replication steps in uninfected bystander cells. Considering
that, L. rhamnosus CRL1505 was able to induce and earlier
and higher production of IFN-β, it can be speculated that
the generation of a fast and effective antiviral state in the
respiratory tract could be involved the higher resistance against
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FIGURE 3 | Modulation of respiratory antiviral immunity by Lactobacillus rhamnosus CRL1505. Proposed mechanism for the distal immunomodulation induced by the
immunobiotic strain L. rhamnosus CRL1505 and the enhancement of the resistance against viral infections through the improvement of the respiratory innate and
adaptive antiviral immune responses.
viral infections. Our group is still investigating how the orally
administered CRL1505 strain can modulate the expression of
type I IFNs and antiviral factors in the respiratory tract. We
have demonstrated increased numbers of CD4+IFN-γ+ T in
the intestine of mice orally treated with L. rhamnosus CRL1505,
and a mobilization of these cells from the gut to the respiratory
mucosa (Villena et al., 2012a; Chiba et al., 2013). Then, the
improved production of IFN-γ and the subsequent stimulation
DCs and macrophages in the lungs could be involved in the
enhanced anti-viral state induced by L. rhamnosus CRL1505
(Figure 3). In line with this hypothesis, we have recently
demonstrated that orally administered CRL1505 strain is able to
increase the production of IFN-β in CD11c+SiglecF+ alveolar
macrophages, which is further augmented in response to TLR3,
RSV, or IFV challenges (submitted for publication). Since the
activation of the innate antiviral immune response is not virus
specific, it is tempting to speculate that L. rhamnosus CRL1505
would improve the resistance to other respiratory viruses as
well (Figure 3).
Respiratory Adaptive Antiviral Immune
Response and L. rhamnosus CRL1505
As mentioned above, orally administered CRL1505 strain
induced the mobilization CD3+CD4+IFN-γ+ T cells from the
gut to the respiratory tract, increasing the local production of
IFN-γ and stimulating antigen presenting cells (Villena et al.,
2012a; Chiba et al., 2013; Zelaya et al., 2014). When lung DCs
populations were evaluated in mice after the oral treatment
with L. rhamnosus CRL1505 it was found increased levels of
both CD11c+CD103+ and CD11c+CD11bhigh DCs. In addition,
both DCs populations showed higher expression of MHC-II
when compared with controls (Villena et al., 2012a; Chiba et al.,
2013). Moreover, IL-12 and IFN-γ were increased specially in
CD11c+CD103+ DCs, the antigen presenting cell population
that has been associated to the generation of Th1 responses in the
respiratory tract (Kitazawa and Villena, 2014). The stimulation
of respiratory DCs further increased the local numbers of
CD3+CD4+IFN-γ+ T cells later in the course of RSV or IFV
infections (Figure 3; Villena et al., 2012a; Chiba et al., 2013).
The improvement in antigen presentation would be associated
not only with the higher levels of IFN-γ in the respiratory
tract but also with the enhanced levels of type I IFNs induced
by the immunobiotic treatment (Villena et al., 2012a; Chiba
et al., 2013). It was reported that DCs produce IFN-α and IFN-
β and undergo maturation in response to the paracrine and
autocrine actions of type I IFNs. Moreover, both IFN-α/β have
been shown to be a crucial link between innate and adaptive
immunity because of their ability to stimulate DCs responses
in vivo (Le Bon and Tough, 2002). The treatment of DCs with
type I IFNs activate these antigen presenting cells enhancing
their expressions of MHC-II, CD40, and CD86 molecules, and
improving their capacity to initiate CD4+ and CD8+ T cells
responses (Montoya et al., 2002; Yoo et al., 2010). Of note, we
were not able to detect improved numbers of CD3+CD8+IFN-
γ+ T cells in the respiratory tract of CRL1505-treated mice
after the challenges with respiratory viruses (Chiba et al., 2013;
Zelaya et al., 2014). Further studies are necessary to find out
whether the immunobiotic strain is able to positively influence
other functions of CD8+ T cells such as their ability to kill
virus-infected cells.
Frontiers in Physiology | www.frontiersin.org 10 June 2020 | Volume 11 | Article 699
Villena and Kitazawa Immunobiotics and Antiviral Immunity
On the other hand, the improved antigen presentation
mediated by L. rhamnosus CRL1505 could also have a beneficial
effect on the respiratory humoral immune response. In support
of this hypothesis, several other laboratories have demonstrated
the ability of orally administered immunobiotics to improve
respiratory and systemic humoral immune responses in front
of viral infections (reviewed in Zelaya et al., 2016). Moreover,
although we have not evaluated the effect of orally administered
CRL1505 strain on the respiratory humoral immune response
in the context of viral infections, we have demonstrated a
beneficial effect on the antibody response to Streptococcus
pneumoniae infection (Salva et al., 2010). Respiratory pathogen
challenges results principally in an IgA response in the airways
while their contact with the deep lung induce an increased
production of pathogen-specific IgG. Then, both types of
antibodies are necessary for the full protection against respiratory
pathogens. In our hands, the oral treatment with L. rhamnosus
CRL1505 significantly increased the levels of anti-pneumococcal
respiratory and serum IgA and IgG antibodies (Salva et al., 2010).
Considering that the enhancement of the specific antibodies
production in the respiratory tract induced by the CRL1505
treatment would be the result of an improved innate immune
response and a better antigenic presentation, it is possible to
think that the immunobiotic treatment would be also capable to
generate a better humoral response against respiratory viruses.
In support of this hypothesis, it was demonstrated that type I
IFNs promote antibody responses in vivo through the stimulation
of DCs (Le Bon et al., 2001). It was shown that type I IFNs
increase the levels of antigen-specific antibodies of all subclasses
of IgG and induced IgG2a and IgG3 antibodies. Furthermore,
type I IFNs combined with nasally administered IFV vaccines
in immunization protocols have been shown to induce effective
humoral immune responses (Bracci et al., 2005).
Respiratory Inflammatory Response and
L. rhamnosus CRL1505
TLR3 has a complex role in viral infections since it was reported
that this PRR mediated both beneficial and detrimental effects
during the course of viral infections such as IFV, RSV, SARS-
CoV, or MERS-CoV (Rudd et al., 2005, 2006; Groskreutz et al.,
2006; Le Goffic et al., 2006; Totura et al., 2015). It was reported
that the inflammatory lesions induced by IFV infection are
diminished in the absence of TLR3 (Le Goffic et al., 2006).
Knockdown of TLR3 significantly reduced the infiltration of
lungs with inflammatory macrophages and CD8+ T cells and
reduce the production of IL-6, IL-12, and CCL5 in response to
IFV infection. On the other hand, it was shown that TLR3 has
minimal effect on lung RSV clearance while this PRR actively
participates in the respiratory inflammatory damage (Rudd et al.,
2005, 2006; Groskreutz et al., 2006). Impaired regulation of
TLR3 activation during the course of RSV infection increased
the production of inflammatory cytokines and chemokines,
promoted the infiltration of inflammatory cells (Rudd et al.,
2005; Groskreutz et al., 2006) and potentiated pathogenic Th2-
biased response in the lung (Rudd et al., 2006) contributing to
respiratory tissue damage and the alteration of lung functionality.
More recently, it was also shown that TLR3 signaling pathway
also participates in the lung inflammatory damage induced
by respiratory coronaviruses infections. It was reported that
the knockdown of the TLR3 adaptor TRIF increased the
susceptibility of mice to SARS-CoV infection (Totura et al.,
2015). Mice lacking TRIF had an aberrant pro-inflammatory
cytokine and chemokine response and an increased infiltration of
neutrophils that correlated with increased pathology of the lung.
These findings highlight the importance of the appropriate
regulation of the TLR3 signaling for generating a balanced
protective respiratory innate immune response against
viruses. Therefore, we focused our attention in evaluating
the effect of orally administered L. rhamnosus CRL1505 in the
inflammatory immune response triggered in the respiratory
tract by TLR3 activation. For this purpose, we utilized the
artificial dsRNA analog and TLR3 ligand poly(I:C) to imitate the
pro-inflammatory alterations induced by viral infections in the
lung. Nasally administered poly(I:C) to infant or adult BALB/c
mice increases the levels of pro-inflammatory cytokines and
chemokines in the respiratory tract, augments the inflammatory
cell recruitment into the lung, induces respiratory epithelial cell
death and impairs the alveolar-capillary barrier (Stowell et al.,
2009; Aeffner et al., 2011; Villena et al., 2012a). We observed
that L. rhamnosus CRL1505 treatment induced quantitative
and kinetic differences in the production of pro- and anti-
inflammatory cytokines in the respiratory tract after TLR3
activation (Villena et al., 2012a). In the first hours after poly(I:C)
administration, the levels of respiratory TNF-α and IL-8 in
CRL1505-treated mice were similar to controls while IL-6 and
CCL2 were significantly higher. Interestingly, 24 h after TLR3
activation, the levels of TNF-α, IL-6, IL-8, and CCL2 were
lower in CRL1505-treated mice than in controls. In addition,
respiratory IL-10 in L. rhamnosus CRL1505-treated mice were
significantly increased during all the studied period (Villena
et al., 2012a). We have reported that CD3+CD4+IL-10+ T cells
are the main source of the immunoregulatory cytokine in the
respiratory tract during the course of viral infection (Chiba
et al., 2013; Zelaya et al., 2014) and that the improvement of
this immune cell population is mediated by the secretion of IL-6
and IL-27 by alveolar macrophages (submitted for publication,
Figure 3). Then, our results indicated that during the early stages,
the production of pro-inflammatory factors would contribute
to viral clearance (Chiba et al., 2013; Zelaya et al., 2014). While
in the later stages, the reduction of inflammatory cytokines and
chemokines together with the improved levels of regulatory
cytokines such as IL-10 would be critical for attenuating the
inflammatory damage in the lungs induced by TLR3 activation
(Villena et al., 2012a), and RSV (Chiba et al., 2013) or IFV
infections (Zelaya et al., 2014).
Coagulation Activation and L. rhamnosus
CRL1505
In order to evaluate the effect of orally administered L. rhamnosus
CRL1505 on the activation of coagulation during the course of
respiratory viral infection we used poly(I:C) challenge as well
as RSV and IFV infections in mice (Zelaya et al., 2014, 2016).
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The inflammatory response triggered by RSV or IFV infection
augment the levels of pro-inflammatory cytokines such as TNF-
α, IL-1β, and IL-6 that induce the secretion of TF by endothelial
cells and monocytes contributing to pathology and lung tissue
injury (Yang and Tang, 2016). In addition, it was reported that
the direct stimulation of endothelial cells with TLR3 ligands
induce the up-regulation of TF and the down-regulation of
thrombomodulin (TM) (Shibamiya et al., 2009). Moreover, in
vivo studies also demonstrated that administration of poly(I:C)
is able to alter vascular permeability and increase the levels of D-
dimers indicating that coagulation and fibrinolysis were triggered
(Wang et al., 2004). Our own in vivo studies were in agreement
with these previous reports since we observed that the nasal
challenge of BALB/c mice with poly(I:C), RSV, or IFV induced
a marked enhancement of lung TF expression and thrombin–
antithrombin complex (TATc) levels in the respiratory tract
while they reduced lung TM expression. These inflammatory–
coagulative modifications were accompanied by respiratory
tissue alterations and impairment of lung function (Zelaya et al.,
2014, 2016). We also were the first in demonstrating that orally
administered CRL1505 strain significantly reduced coagulation
activation in blood and in the respiratory tract after the nasal
challenge with poly(I:C) or respiratory viruses (Zelaya et al.,
2014). Lower levels of respiratory TATc, reduced expression of TF
and increased expression of lung TMwere found in L. rhamnosus
CRL1505-treated mice when compared to controls. In addition,
by using anti-IL-10R blocking antibodies we demonstrated that
IL-10 is important for the regulation of coagulation induced
by the immunobiotic CRL1505 strain (Zelaya et al., 2014). IL-
10 induced by L. rhamnosus CRL1505 administration is able to
attenuate the expression of TF in inflammatory macrophages
recruited in response to TLR3 activation of viral infection.
Intestinal Antiviral Immune Response and
L. rhamnosus CRL1505
We have also advanced in the characterization of the
immunomodulatory and antiviral effects of the CRL1505 strain
in the intestinal mucosa (Figure 3). In vitro studies performed in
intestinal epithelial cells showed that L. rhamnosus CRL1505 was
able to improve the production of type I interferons (Villena et al.,
2014). Moreover, transcriptomic studies revealed a remarkable
ability of the CRL1505 strain to enhance the expression of IFN-α
and IFN-β as well as the antiviral factors Nplr3, Oas1, OasLA,
Mx2, and RNAseL in intestinal epithelial cells when compared to
other immunomodulatory lactobacilli (Albarracin et al., 2017,
2020). In vitro experiments also demonstrated that L. rhamnosus
CRL1505 is capable of augmenting the expression of MHC-II
and CD80 and the production of IFN-γ in intestinal DCs and
macrophages (Villena et al., 2014). The immunological changes
induced by the CRL1505 strain in intestinal non-immune
and immune cells correlated with the improved resistance
of children to rotavirus infection (Villena et al., 2012a). We
have also performed in vivo studies to evaluate the impact
of L. rhamnosus CRL1505 on the intestinal inflammatory
response triggered by TLR3 activation. Using a murine model of
intraperitoneal challenge with poly(I:C) to induce an intestinal
inflammatory response, we demonstrate that oral administration
of L. rhamnosus CRL1505 differentially modulates the intestinal
antiviral immune response mediated by TLR3 and intraepithelial
lymphocytes (Tada et al., 2016). The beneficial effects of the
CRL1505 strain were associated with its ability to decrease the
production of inflammatory cytokines including IL-15, increase
IL-10 levels and reduce the number of CD3+NK1.1+ and
CD8αα+NKG2D+ cells in the intestine. Our results indicated
that the immunobiotic treatment was capable of reducing
damage to intestinal epithelial cells mediated by the TLR3-IL-15-
CD8αα+NKG2D+ cells axis (Tada et al., 2016). Then, we have
conclusively demonstrated that a dietary intervention with L.
rhamnosus CRL1505 is able to increase resistance to challenge
with intestinal virus, reducing viral replication and favorably
modulating the inflammatory response triggered by the viral
attack (Villena et al., 2012a, 2014; Tada et al., 2016; Albarracin
et al., 2017, 2020).
COULD IMMUNOBIOTICS HAVE ANY
BENEFIT IN THE SARS-CoV-2 PANDEMIC?
As stated before, a clear understanding of the immunological
processes underlying the clinical manifestations of COVID-19 is
vital for the rational design of effective therapies aimed to prevent
or ameliorate the severity of the disease. Here, we provided
an overview of the current knowledge of the pathophysiology
and the immune response to SARS-CoV-2 infection (Figure 4).
In addition, we have summarized the cellular and molecular
information gathered during this decade of work regarding the
effect of L. rhamnosus CRL1505 in the beneficial modulation
of the mucosal antiviral immune response. This comparative
analysis allows us to postulate that the use of immunobiotic
microorganisms such as the CRL1505 strain could be beneficial in
the prevention and/or the reduction of the severity of infections
caused by emerging respiratory viruses such as SARS-CoV-2
(Figure 4).
One of the most important questions asked by scientists
regarding the efficacy of immunobiotics in reducing infections
is whether they can be used as both preventive and therapeutic
tools. Data from animal and clinical studies demonstrated
that immunobiotic interventions are mostly effective in the
prevention of respiratory infections while they rarely influence
the course of infections once the pathogen has started its
replication in the host (Zelaya et al., 2016; Villena et al.,
2019). Thus, in the context of the SARS-CoV-2 pandemic,
immunobiotics should be considered as a strategy to strengthen
the respiratory immune system of healthy people, rather than as
a therapeutic option in patients who have already been infected
with the virus. On the other hand, the characteristics of the host
in which the immunobiotics are going to be applied would be also
determinant for their effectiveness. One of the most important
findings made by clinicians and scientists since the COVID-19
pandemic began is the fact that distinct population groups may
react differently to SARS-CoV-2 infection. Jamilloux et al. (2020)
defined three phenotypes in COVID-19 patients according to
the infection’s progression and extent: (a) patients with mild
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FIGURE 4 | Potential beneficial effects of Lactobacillus rhamnosus CRL1505 against SARS-CoV-2 infection. Proposed potential benefits in the reduction of the
incidence and severity of COVID-19 induced by nutritional interventions with the immunobiotic strain L. rhamnosus CRL1505. The principal pathological and
immunological alterations during SARS-CoV-2 infection were summarized from Jamilloux et al. (2020), Tay et al. (2020), Merad and Martin (2020), and Chen N. et al.
(2020). The beneficial effects of L. rhamnosus CRL1505 in the respiratory tract were summarized from Villena et al. (2012a), Chiba et al. (2013), and Zelaya et al. (2014).
The beneficial effects of L. rhamnosus CRL1505 in the intestinal tract were summarized from Villena et al. (2014), Tada et al. (2016), and Albarracin et al. (2017, 2020).
and non-specific symptoms who will not progress to severe
disease (mild group), (b) patients with localized inflammation,
pneumonia and requiring hospitalization (moderate group), and,
(c) patients that develop ARDS, systemic hyperinflammation,
and multiple organ failure who will require critical care
management and are at risk of fatal outcome (severe group).
Children, adolescents, and immunocompetent adults are in the
mild/moderate group, which represent the 95% of the SARS-
CoV-2-infected persons. On the other hand, 5% of COVID-
19 patients are adults with comorbidities and the elderly who
are at high risk to develop severe disease (Jamilloux et al.,
2020). These two groups, “mild/moderate,” and “severe,” greatly
differ in the intensity and the kinetics of the immune responses
triggered upon SARS-CoV-2 infection (Figure 5). Thus, we can
hypothesize that the effectiveness of the nutritional interventions
with immunobiotics will depend on the COVID-19 phenotype
group considered.
It is tempting to speculate that immunobiotics would
have a relevant impact on SARS-CoV-2 infection in the
“mild/moderate” group. As highlighted before, this coronavirus
is capable of both impair the innate antiviral immune response
and induce a hyperactivation of the immune system. However,
these two changes in the immune system are not simultaneous
(Figure 5) and moreover the latter seems to ensue from the
former (Jamilloux et al., 2020; Merad and Martin, 2020; Tay
et al., 2020). The efficient viral clearance induced by the activities
of type I IFNs in the earlier stages of the infection is a key
to prevent the viral dissemination, the T cell exhaustion, and
the subsequent hypercytokinemia. Then, the improved type I
IFNs response in the early stage of infection would be capable
of avoiding viral replication or reducing the severity of the
disease. In support of statement, it was suggested that SARS-
CoV-2 have a lesser type I IFN antagonism compared to SARS-
CoV (Perlman and Netland, 2009) and in vitro experiments have
demonstrated that SARS-CoV-2 displays a greater sensitivity to
type I IFNs than SARS-CoV (Lokugamage et al., 2020).Moreover,
mild/moderate infection by SARS-CoV-2 has been associated
with a potent type I IFNs response in the respiratory tract
(Zhou et al., 2020) and blood (Trouillet-Assant et al., 2020).
The efficient management of viral infection in the early stages
would also enable the generation of an adequate and timely Th1
response. In fact, improved levels of IFN-γ and Th1 cells in
the respiratory tract have been associated to the mild/moderate
disease while IFN-γ was not found to be elevated in the sera
or respiratory tract of patients with severe forms of COVID-
19 (Xiong et al., 2020). Furthermore, lower levels of IFN-γ
have been proposed as marker of poorer outcomes (Lagunas-
Rangel and Chávez-Valencia, 2020). On the other hand, the rapid
control of virus replication would enable the host to be protect
against disease progression by limiting epithelial damage, local
inflammation, and accumulation of pathological macrophage
populations (Jamilloux et al., 2020; Merad and Martin, 2020; Tay
et al., 2020).
Considering that immunobiotic strains such as L. rhamnosus
CRL1505 were shown to induce an earlier and enhanced
production of type I IFNs and activation of the inflammatory
response in the respiratory tract in response to viral challenges,
followed by an improved production of IFN-γ by Th1 cells and
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FIGURE 5 | Hypothesis of the beneficial effects of preventive immunobiotic intervention on SARS-CoV-2 infection. The kinetics and intensity of immune actors
involved in the response to SARS-CoV-2, viral load and COVID-19 severity are shown according to Jamilloux et al. (2020) in both “mild/moderate” and “severe”
susceptible hosts. Optimal times for therapeutic interventions proposed to ameliorate disease severity are also shown (left panels). The potential modulation of the
kinetics and intensity of immune response, viral load, and disease severity by preventive nutritional immunobiotic interventions for low and high susceptible hosts are
shown in the right panels.
an efficient regulation of inflammation (Villena et al., 2012a;
Chiba et al., 2013; Zelaya et al., 2014), the preventive nutritional
immunobiotic intervention in the “mild/moderate” group could
help to avoid the infection or reduce its severity and duration
(Figure 5). In addition, immunobiotics could help to diminish
community SARS-CoV-2 virus circulation by reducing viral loads
in asymptomatic patients. This beneficial effect of immunobiotics
could be particularly relevant since it was demonstrated that
children tend not to develop severe disease despite being
capable of experiencing high viral titers (Kam et al., 2020).
Furthermore, immunobiotics could contribute to the reduction
of the circulation of other respiratory pathogens such as IFV and
S. pneumoniae (Figure 4), which increase the risk of mortality in
the “severe” group of COVID-19 patients (Chen N. et al., 2020;
Ding et al., 2020; Huang et al., 2020; Wang J. et al., 2020; Wu
et al., 2020).
On the other hand, the potential beneficial effects of
immunobiotics in the “severe” group must be extrapolated
more carefully, since in this kind of hosts the immune
responses are not only conditioned by the viral infection
but also by the alterations associated with the age and/or
the presence of other pathologies. As mentioned before, the
most important characteristic of the response to SARS-CoV-2
infection in the “severe” group is the impaired innate antiviral
response and the subsequent hyperinflammation (Figure 5).
The “cytokine storm” and the exuberant inflammation lead to
ARDS, disseminated intravascular coagulation, multiple organ
failure, and death (Jamilloux et al., 2020). The defective or
delayed first line of respiratory antiviral defense, followed
by the persistent production of inflammatory cytokines such
as IL-6, IL-1β, and TNF-α, results in an increased viral
replication and dissemination, desquamation of alveolar cells,
hyaline membrane formation, pulmonary edema, impaired
clearance of apoptotic cells by dysfunctional macrophages,
hemophagocytosis, coagulopathy, and ARDS (Chen N. et al.,
2020; Jamilloux et al., 2020; Merad and Martin, 2020; Tay et al.,
2020). Immunosuppressive therapies have been proposed for
the limitation of the inflammatory damage in severe COVID-
19 patients. Individual cytokine antagonists such as blocking
antibodies directed to IL-1β or IL-6 were found to be helpful in
the recovery of some patients (Jamilloux et al., 2020). However,
because of our limited understanding of the inflammatory
pathways involved the severe complications of SARS-CoV-
2 infection and the wide diversity of patients with different
pathologies in the “severe” group, some of these strategies
targeting only one cytokine could have detrimental effects in
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certain type of patients or if they are applied in an incorrect
stage of the COVID-19 disease. In contrast, the preventive
immunobiotic intervention would induce an earlier influence on
several cytokines simultaneously as it has been demonstrated
in animal models (Villena et al., 2012a; Chiba et al., 2013;
Zelaya et al., 2014). The rapid regulation of inflammatory
cytokines and the improvement of IL-10 during the course of
respiratory viral infections would allow a reduction of lung
tissue damage and could help to delay the appearance of the
most harmful effects of the infection, giving more time to
clinicians for applying therapies to protect patients from death
(Figure 5). In addition, immunobiotics could help to diminish
the incidence and/or severity of thrombotic alterations associated
to the respiratory viral infection through the modulation
of inflammation (Figure 4). In support of this hypothesis,
some human clinical trials have demonstrated the ability of
immunobiotics to improve the immune health of patients with
diseases such as type 2 diabetes, obesity (reviewed in Sáez-Lara
et al., 2016), hypertension, and cardiovascular diseases (reviewed
in Vasquez et al., 2019). However, much more rigorous clinical
and mechanistic studies are necessary to propose immunobiotics
as palliatives for the severity of COVID-19 in high-risk patients.
Another potential beneficial effect of the application of
immunobiotics in the prevention of SARS-CoV-2 infection is
related to their impact on intestinal immunity. Diarrhea is
a frequent symptom in 10% of patients infected with SARS-
CoV-2 and increasing evidence also indicates possible fecal-
oral transmission. Moreover, some patients have diarrhea in
the absence of respiratory symptoms, and this may lead to
underestimation of COVID-19 cases (reviewed in D’Amico
et al., 2020). In this context, considering the ability of
some immunobiotic strains to improve the type I IFNs
response of intestinal epithelial cells, the activation of intestinal
antigen presenting cells as well as to beneficially regulate the
inflammatory response (Figure 3; Villena et al., 2012a, 2014;
Tada et al., 2016; Albarracin et al., 2017, 2020), preventive
nutritional interventions with immunobiotics could help in
reducing the incidence and severity of gastrointestinal symptoms
and the fecal-oral transmission (Figure 4). In support of this
hypothesis, several research works have demonstrated the efficacy
of immunobiotics for improving immune responses against
coronaviruses in different animals. It was demonstrated that L.
plantarum Probio-38 and L. salivarius Probio-37 were capable
of reducing the replication of transmissible gastroenteritis
coronavirus (TGEV), a highly contagious enteric pathogen in
pigs, in the porcine ST cell line (Rejish Kumar et al., 2010).
Similarly, Enterococcus faecium NCIMB 10415 reduced the
replication of TGEV in ST cells and the improved production of
NO, IL-6, and IL-8 were associated to its beneficial effect (Chai
et al., 2013). A mixture of probiotic strains was also capable
of strengthen the immune system of pigs infected with porcine
epidemic diarrhea (PED) coronavirus and improved their
reproductive performance (Tsukahara et al., 2018). Interestingly,
it was recently reported that a multi-strain probiotic preparation
significantly reduced the fecal shedding of the feline coronavirus
(FCoV) in cats naturally infected with the pathogen (Addie et al.,
2020).
The gastrointestinal alterations in COVID-19 patients can be
associated not only to viral replication but also to the disruption
of the intestinal microbiota by the antibiotic treatments often
necessary in this situation (D’Amico et al., 2020). In this
circumstance, it is also plausible that immunobiotics could also
be applied for the treatment of COVID-19 patients in order
to restore the intestinal microbiota and the optimal function
of the immune system. In this regard, the China’s National
Health Commission recommended the use of probiotics for the
treatment of patients with severe COVID-19 in order to preserve
intestinal balance and to prevent secondary bacterial infections
(Gao et al., 2020).
Finally, an additional important aspect that has to be
carefully considered for the potential application of a nutritional
immunobiotic intervention in the COVID-19 pandemic is the
selection of the most appropriate immunobiotic(s) strain(s).
Various probiotic lactic acid bacteria with immunomodulatory
activities have been tested in their abilities to improve the
resistance to intestinal infections and only a limited number
of strains were proved to be effective in the modulation of
the antiviral immunity (reviewed in Villena et al., 2016, 2019).
Moreover, most of the research related to the beneficial effect
of immunobiotics on the host’s antiviral immune responses
has focused on the intestinal tract while there is less scientific
evidence about the capacity of immunobiotics to modulate
responses in distant mucosal sites such as the respiratory tract.
This is probably related to the fact that immunobiotics with the
ability to improve antiviral defenses in both the intestine and
the respiratory tract belong to a group with a limited number of
members (Villena et al., 2016, 2019; Zelaya et al., 2016). Our own
studies have clearly shown that this specific immunomodulatory
property is a strain-dependent characteristic. In our hands,
immunobiotic strains such as L. plantarum CRL1506 that is
capable to stimulate the antiviral intestinal immunity (Villena
et al., 2012a, 2014; Tada et al., 2016; Albarracin et al., 2017)
was not able to influence respiratory antiviral immune responses
after its oral administration (Villena et al., 2012a; Chiba et al.,
2013; Zelaya et al., 2014). Therefore, the immunobiotic strains
proposed to strengthen the population’s immune system during
viral epidemics or pandemics should have a strong scientific
background that clearly supports their ability to modulate
the mucosal antiviral immunity. In addition, the selection
of new antiviral immunobiotic strains that have different
biotechnological properties could enhance the development of
various types of functional foods that could be used in nutritional
immunobiotic interventions around the world to reduce the
incidence and severity of intestinal and pulmonary infections
caused by viruses such as the SARS-CoV-2. In this regard,
our recent in vitro and in vivo studies demonstrated that L.
plantarum MPL16 modulated the intestinal and respiratory
antiviral immunity in a similar way as the CRL1505 strain
(Albarracin et al., 2020). Whereas, L. rhamnosus CRL1505 has
been used mainly in dairy functional products, the MPL16 strain
has shown a remarkable ability to growth and ferment wakame
(Undaria pinnatifida) that is the most popular edible brown
algae in Asian countries. Then, the different biotechnological
properties of immunobiotics such as L. plantarum MPL16 could
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potentiate the development of non-dairy functional foods with
the ability to improve antiviral immunity in the intestine and the
respiratory tract.
CONCLUSIONS
As the SARS-CoV-2 pandemic expands, scientists have made
great advances in the knowledge of the genome characteristics
and the infection biology of this virus that will allow the
development of new vaccines and therapeutics in the future.
However, in order to favorably affect the trajectory of this
pandemic and mitigate as much as possible its detrimental
effect on public health and economy, all the available scientific
resources should be put at the service of the community. More
than a decade of research investigating the cellular and molecular
mechanisms involved in the improvement of respiratory antiviral
defenses by beneficial immunobiotic microorganisms clearly
indicate their potential to favorably influence the immune
response against SARS-CoV-2 virus. The demonstration of ability
of beneficial microorganisms to enhance type I interferons
and antiviral factors in the respiratory tract, stimulate Th1
response and antibodies production, and regulate inflammation
and coagulation activation during the course of viral infections
reducing tissue damage and preserving lung functionally, provide
solid scientific basis for proposing immunobiotic nutritional
interventions to help in the strengthening of the immune system
and the reduction of the incidence and severity of COVID-19.
In addition, taking into consideration that scientists speculate
that this new virus will accompany humanity from now on,
studies in experimental animals as well as clinical trials that
conclusively demonstrate the beneficial effect of immunobiotics
on SARS-CoV-2 infection, particularly in high-risk populations,
could enhance their application to mitigate the virus-associated
detrimental effects of the immune system. If this approach is
scientifically validated, rapid repurposing of immunobiotics such
as L. rhamnosusCRL1505 or L. plantarumMPL16will be effective
and timely in the fight against COVID-19.
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